Adam N.R. Cartwright

Adam N.R. Cartwright

Auto-generated profile, based on publicly available information

Adam N.R. Cartwright

Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDaniela Schmid
Daniela Schmid
CPChun Gwon Park
Chun Gwon Park
CHChristina A. Hartl
Christina A. Hartl
NSNikita Subedi
Nikita Subedi
ACAdam N. Cartwright
Adam N. Cartwright
MGMichael S. Goldberg
Michael S. Goldberg
Targeted delivery of compounds to particular cell subsets can enhance therapeutic index by concentrating their action on the cells of interest. Because attempts to target tumors directly have yielded limited benefit, we instead target endogenous immune cell subsets in the circulation that can migrate actively into tumors. We describe antibody-targeted nanoparticles that bind to CD8+ T cells in the blood, lymphoid tissues, and tumors of mice. PD-1+ T cells are successfully targeted in the circulation and tumor. The delivery of an inhibitor of TGFβ signaling to PD-1-expressing cells extends the survival of tumor-bearing mice, whereas free drugs have no effect at such doses. This modular platform also enables PD-1-targeted delivery of a TLR7/8 agonist to the tumor microenvironment, increasing the proportion of tumor-infiltrating CD8+ T cells and sensitizing tumors to subsequent anti-PD-1. Targeted delivery of immunotherapy to defined subsets of endogenous leukocytes may be superior to administration of free drugs.

4 April 2023
Verified
Other
Open access
ACAdam N.R. Cartwright
Adam N.R. Cartwright
SSShengbao Suo
Shengbao Suo
SBSoumya Badrinath
Soumya Badrinath
SKSushil J Kumar
Sushil J Kumar
JMJohannes Melms
Johannes Melms
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
Supplementary Table 1. Summary of proposed mechanisms of MDSC-mediated suppression.

3 April 2023
Verified
Other
Open access
SKSushil J Kumar
Sushil J Kumar
ZZZexian Zeng
Zexian Zeng
ABArchis Bagati
Archis Bagati
RTRong En Tay
Rong En Tay
LSLionel A. Sanz
Lionel A. Sanz
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
CRISPR screen in tumor-infiltrating T cells

3 April 2023
Verified
Other
Open access
SKSushil J Kumar
Sushil J Kumar
ZZZexian Zeng
Zexian Zeng
ABArchis Bagati
Archis Bagati
RTRong En Tay
Rong En Tay
LSLionel A. Sanz
Lionel A. Sanz
KWKai W. Wucherpfennig
Kai W. Wucherpfennig

3 April 2023
Verified
Other
Open access
SKSushil J Kumar
Sushil J Kumar
ZZZexian Zeng
Zexian Zeng
ABArchis Bagati
Archis Bagati
RTRong En Tay
Rong En Tay
LSLionel A. Sanz
Lionel A. Sanz
KWKai W. Wucherpfennig
Kai W. Wucherpfennig